Claus Bachert

← Back to Ghent University

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

1. European Position Paper on Rhinosinusitis and Nasal Polyps 2020

   2020 · 5,888 citations

2. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

   2008 · 4,738 citations

3. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists

   2012 · 2,400 citations

4. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision

   2017 · 1,984 citations

5. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

   2019 · 1,563 citations

6. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists

   2012 · 1,182 citations

7. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers

   2016 · 1,162 citations

8. International consensus statement on allergy and rhinology: rhinosinusitis 2021

   2020 · 959 citations

9. Allergic rhinitis

   2020 · 942 citations

10. Rhinosinusitis: Establishing definitions for clinical research and patient care

    2004 · 851 citations

11. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis

    2016 · 796 citations

12. Differentiation of chronic sinus diseases by measurement of inflammatory mediators

    2006 · 774 citations

13. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma

    2012 · 745 citations

14. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials

    2020 · 739 citations

15. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation

    2001 · 702 citations

16. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation

    2011 · 676 citations

17. Consensus statement * on the treatment of allergic rhinitis

    2000 · 662 citations

18. Practical guide to skin prick tests in allergy to aeroallergens

    2011 · 646 citations

19. Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis

    2011 · 633 citations

20. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial

    2021 · 628 citations

21. Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs

    2012 · 626 citations

22. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease

    2008 · 620 citations

23. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: A multicenter study in Europe, Asia, and Oceania

    2016 · 616 citations

24. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence

    2019 · 609 citations

25. Otolaryngology‐Head and Neck Surgery

    2004 · 559 citations

← Return to the university profile